These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2206633)

  • 21. Preclinical stages in subjects at risk for neurological disorders: can PET-FDG tell us more?
    Azari NP; Pietrini P
    J Neurol; 1995 Jan; 242(2):112-4. PubMed ID: 7707087
    [No Abstract]   [Full Text] [Related]  

  • 22. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography.
    Wolkin A; Jaeger J; Brodie JD; Wolf AP; Fowler J; Rotrosen J; Gomez-Mont F; Cancro R
    Am J Psychiatry; 1985 May; 142(5):564-71. PubMed ID: 3872603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain glucose metabolism in Parkinson's disease.
    Metter EJ; Kuhl DE; Riege WH
    Adv Neurol; 1990; 53():135-9. PubMed ID: 2239454
    [No Abstract]   [Full Text] [Related]  

  • 24. Functional effects of striatal dysfunction in Parkinson disease.
    Holthoff-Detto VA; Kessler J; Herholz K; Bönner H; Pietrzyk U; Würker M; Ghaemi M; Wienhard K; Wagner R; Heiss WD
    Arch Neurol; 1997 Feb; 54(2):145-50. PubMed ID: 9041855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversible striatal hypermetabolism in a case of Sydenham's chorea.
    Goldman S; Amrom D; Szliwowski HB; Detemmerman D; Goldman S; Bidaut LM; Stanus E; Luxen A
    Mov Disord; 1993 Jul; 8(3):355-8. PubMed ID: 8341301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated basal ganglia glucose metabolism in cyclosporine neurotoxicity: a positron emission tomography imaging study.
    Meyer MA
    J Neuroimaging; 2002 Jan; 12(1):92-3. PubMed ID: 11826612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease.
    Eidelberg D; Takikawa S; Moeller JR; Dhawan V; Redington K; Chaly T; Robeson W; Dahl JR; Margouleff D; Fazzini E
    Ann Neurol; 1993 May; 33(5):518-27. PubMed ID: 8498828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crossed cerebellar and uncrossed basal ganglia and thalamic diaschisis in Alzheimer's disease.
    Akiyama H; Harrop R; McGeer PL; Peppard R; McGeer EG
    Neurology; 1989 Apr; 39(4):541-8. PubMed ID: 2784550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing patterns of glucose metabolism during the course of subacute sclerosing panencephalitis as measured with 18FDG-positron-emission tomography.
    Huber M; Pawlik G; Bamborschke S; Fink GR; Karbe H; Schlenker M; Bewermeyer H; Heiss WD
    J Neurol; 1992 Mar; 239(3):157-61. PubMed ID: 1573420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neural networks: neural systems vi: basal ganglia.
    Tamminga C; Holcomb H
    Am J Psychiatry; 2001 Feb; 158(2):185. PubMed ID: 11156797
    [No Abstract]   [Full Text] [Related]  

  • 31. [Striatal 18F-dopa uptake measuring nigrostriatal function].
    Otsuka M; Masuda K; Kato M
    Nihon Rinsho; 1991 Jul; 49(7):1532-6. PubMed ID: 1909388
    [No Abstract]   [Full Text] [Related]  

  • 32. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy.
    Goffinet AM; De Volder AG; Gillain C; Rectem D; Bol A; Michel C; Cogneau M; Labar D; Laterre C
    Ann Neurol; 1989 Feb; 25(2):131-9. PubMed ID: 2784043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism.
    Martin WR; Stoessl AJ; Adam MJ; Ammann W; Bergstrom M; Harrop R; Laihinen A; Rogers JG; Ruth TJ; Sayre CI
    Adv Neurol; 1987; 45():95-8. PubMed ID: 3103398
    [No Abstract]   [Full Text] [Related]  

  • 34. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation-induced meningioma evaluated with positron emission tomography with fludeoxyglucose F 18.
    Kado H; Ogawa T; Hatazawa J; Iwase M; Kanno I; Okudera T; Uemura K
    AJNR Am J Neuroradiol; 1996 May; 17(5):937-8. PubMed ID: 8733970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography and central neurotransmitter systems in movement disorders.
    Weeks RA; Brooks DJ
    Fundam Clin Pharmacol; 1994; 8(6):503-17. PubMed ID: 7721227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome.
    Przedborski S; Goldman S; Levivier M; Giladi N; Bidaut LM; Hildebrand J; Stanus E; Labar D; Luxen A
    Mov Disord; 1993 Jul; 8(3):391-5. PubMed ID: 8341311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease process and drug treatments in Parkinson's disease.
    Leenders KL
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020
    [No Abstract]   [Full Text] [Related]  

  • 39. Human brain receptors, IV. Human in vivo receptor imaging.
    Tamminga CA; Conley RR; Wong DF
    Am J Psychiatry; 1994 May; 151(5):639. PubMed ID: 8166302
    [No Abstract]   [Full Text] [Related]  

  • 40. Postinjection L-phenylalanine increases basal ganglia contrast in PET scans of 6-18F-DOPA.
    Doudet DJ; McLellan CA; Aigner TG; Wyatt R; Adams HR; Miyake H; Finn RT; Cohen RM
    J Nucl Med; 1991 Jul; 32(7):1408-13. PubMed ID: 1906094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.